Clinical Laserthermia Systems AB (CLS B) - Product Pipeline Analysis, 2022 Update

Summary

Clinical Laserthermia Systems AB (CLS) is a medical equipment company that develops and markets instruments for the treatment of cancer. The company offers Tranberg, a thermal therapy system developed for image guided high precision treatment of soft tissues and ablation procedures. Tranberg is approved in Europe for immune stimulating interstitial thermotherapy (imILT) treatments. CLS is also evaluating its products for treating focal laser ablation and other combined therapies. The company offers its product to hospitals and specialist clinics involved surgical oncology and oncologic interventional radiology and has operations for clinical studies in Italy, France, Germany, UK, Sweden, and Portugal for different indications. CLS is headquartered Lund, Sweden.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Clinical Laserthermia Systems AB
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Clinical Laserthermia Systems AB Company Overview
Clinical Laserthermia Systems AB Company Snapshot
Clinical Laserthermia Systems AB Pipeline Products and Ongoing Clinical Trials Overview
Clinical Laserthermia Systems AB – Pipeline Analysis Overview
Business Description
Clinical Laserthermia Systems AB - Key Facts
Clinical Laserthermia Systems AB - Major Products and Services
Clinical Laserthermia Systems AB Pipeline Products by Development Stage
Clinical Laserthermia Systems AB Ongoing Clinical Trials by Trial Status
Clinical Laserthermia Systems AB Pipeline Products Overview
imILT Software
imILT Software Product Overview
MRI-Integrated Thermometry Software
MRI-Integrated Thermometry Software Product Overview
ThermoGuide
ThermoGuide Product Overview
ThermoGuide Clinical Trial
Tranberg Cancer Immunotherapy System - Breast Cancer
Tranberg Cancer Immunotherapy System - Breast Cancer Product Overview
TRANBERG Cancer Immunotherapy System - Pancreatic Cancer
TRANBERG Cancer Immunotherapy System - Pancreatic Cancer Product Overview
TRANBERG Cancer Immunotherapy System - Skin Cancer
TRANBERG Cancer Immunotherapy System - Skin Cancer Product Overview
TRANBERG Cancer Immunotherapy System - Small Liver Metastases
TRANBERG Cancer Immunotherapy System - Small Liver Metastases Product Overview
TRANBERG Cancer Immunotherapy System - Solid Cancers
TRANBERG Cancer Immunotherapy System - Solid Cancers Product Overview
Tranberg CLS Thermal Therapy System
Tranberg CLS Thermal Therapy System Product Overview
Tranberg CLS Thermal Therapy System Clinical Trial
Tranberg CLS Thermal Therapy System - Glioblastoma Ablation
Tranberg CLS Thermal Therapy System - Glioblastoma Ablation Product Overview
Tranberg CLS Thermal Therapy System - Glioblastoma Ablation Clinical Trial
Tranberg CLS Thermal Therapy System - Prostate Cancer
Tranberg CLS Thermal Therapy System - Prostate Cancer Product Overview
Tranberg CLS Thermal Therapy System - Prostate Cancer Clinical Trial
Clinical Laserthermia Systems AB - Key Competitors
Clinical Laserthermia Systems AB - Key Employees
Clinical Laserthermia Systems AB - Key Employee Biographies
Clinical Laserthermia Systems AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Clinical Laserthermia Systems AB, Recent Developments
Nov 17, 2022: Clinical Laserthermia Systems AB publishes interim report January – September 2022
Nov 17, 2022: Clinical Laserthermia Systems publishes interim report January - September 2022
Sep 30, 2022: Clinical Laserthermia Systems AB announces last day of trading in BTU and first day of trading in warrants of series TO 5 B
Aug 10, 2022: The Board of Directors of Clinical Laserthermia Systems AB (publ) resolves on a rights issue of units for an initial amount of approximately 69.3 MSEK
May 18, 2022: Dan J. Mogren appointed as permanent CEO of Clinical Laserthermia Systems
Apr 01, 2022: CLS’s acting CEO Dan J. Mogren returns to work after medical leave
Dec 02, 2021: BioStock: CLS re-releases sterile disposable instruments on the European market
Nov 18, 2021: CLS Again releases TRANBERG sterile disposable products into the US Market
Jan 24, 2020: CLS presents image-guided Laser Thermotherapy System at 30th Annual Prostate Cancer Update Conference
Dec 10, 2019: CLS presents Image-Guided Laser Thermotherapy enhancements at ESIR - European School of Interventional Radiology Conference
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Clinical Laserthermia Systems AB Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Clinical Laserthermia Systems AB Pipeline Products by Equipment Type
Table 3: Clinical Laserthermia Systems AB Pipeline Products by Indication
Table 4: Clinical Laserthermia Systems AB, Key Facts
Table 5: Clinical Laserthermia Systems AB, Major Products and Services
Table 6: Clinical Laserthermia Systems AB Number of Pipeline Products by Development Stage
Table 7: Clinical Laserthermia Systems AB Pipeline Products Summary by Development Stage
Table 8: Clinical Laserthermia Systems AB Ongoing Clinical Trials by Trial Status
Table 9: Clinical Laserthermia Systems AB Ongoing Clinical Trials Summary
Table 10: imILT Software - Product Status
Table 11: imILT Software - Product Description
Table 12: MRI-Integrated Thermometry Software - Product Status
Table 13: MRI-Integrated Thermometry Software - Product Description
Table 14: ThermoGuide - Product Status
Table 15: ThermoGuide - Product Description
Table 16: ThermoGuide - Evaluation of the Safety and Feasibility of Magnetic Resonance Guided Focused Laser Ablation for Localized Prostate Cancer in Low to Intermediate Risk Patients
Table 17: ThermoGuide - Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesion Using the Tranberg Thermal Therapy System and Tranberg Thermoguide Workstation
Table 18: Tranberg Cancer Immunotherapy System - Breast Cancer - Product Status
Table 19: Tranberg Cancer Immunotherapy System - Breast Cancer - Product Description
Table 20: TRANBERG Cancer Immunotherapy System - Pancreatic Cancer - Product Status
Table 21: TRANBERG Cancer Immunotherapy System - Pancreatic Cancer - Product Description
Table 22: TRANBERG Cancer Immunotherapy System - Skin Cancer - Product Status
Table 23: TRANBERG Cancer Immunotherapy System - Skin Cancer - Product Description
Table 24: TRANBERG Cancer Immunotherapy System - Small Liver Metastases - Product Status
Table 25: TRANBERG Cancer Immunotherapy System - Small Liver Metastases - Product Description
Table 26: TRANBERG Cancer Immunotherapy System - Solid Cancers - Product Status
Table 27: TRANBERG Cancer Immunotherapy System - Solid Cancers - Product Description
Table 28: Tranberg CLS Thermal Therapy System - Product Status
Table 29: Tranberg CLS Thermal Therapy System - Product Description
Table 30: Tranberg CLS Thermal Therapy System - A Phase II Study to Evaluate Outpatient Magnetic Resonance Image-guided Laser Focal Therapy for Prostate Cancer: A 20-year Survival Study
Table 31: Tranberg CLS Thermal Therapy System - Clinical Study for Evaluation of Safety and Efficacy of MRI-guided Laser Ablation with Tranberg Thermal Therapy System in Prostate Cancer Subjects
Table 32: Tranberg CLS Thermal Therapy System - Glioblastoma Ablation - Product Status
Table 33: Tranberg CLS Thermal Therapy System - Glioblastoma Ablation - Product Description
Table 34: Tranberg CLS Thermal Therapy System - Glioblastoma Ablation - Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesion Using the Tranberg Thermal Therapy System and Tranberg Thermoguide Workstation
Table 35: Tranberg CLS Thermal Therapy System - Prostate Cancer - Product Status
Table 36: Tranberg CLS Thermal Therapy System - Prostate Cancer - Product Description
Table 37: Tranberg CLS Thermal Therapy System - Prostate Cancer - A Study to Evaluate the Focal Laser Ablation Treatment in Patients with Localized Prostate Cancer
Table 38: Tranberg CLS Thermal Therapy System - Prostate Cancer - Evaluation of the Safety and Feasibility of Magnetic Resonance Guided Focused Laser Ablation for Localized Prostate Cancer in Low to Intermediate Risk Patients
Table 39: Tranberg CLS Thermal Therapy System - Prostate Cancer - MRI Guided Focal Laser Ablation of Prostate Cancer
Table 40: Tranberg CLS Thermal Therapy System - Prostate Cancer - Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer
Table 41: Clinical Laserthermia Systems AB, Key Employees
Table 42: Clinical Laserthermia Systems AB, Key Employee Biographies
Table 43: Clinical Laserthermia Systems AB, Subsidiaries
Table 44: Glossary
List of Figures
Figure 1: Clinical Laserthermia Systems AB Pipeline Products by Equipment Type
Figure 2: Clinical Laserthermia Systems AB Pipeline Products by Development Stage
Figure 3: Clinical Laserthermia Systems AB Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings